These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 25703519)

  • 1. Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants.
    Riva N; Ageno W
    Semin Thromb Hemost; 2015 Mar; 41(2):178-87. PubMed ID: 25703519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
    Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
    Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?
    Dzeshka MS; Lip GY
    Trends Cardiovasc Med; 2015 May; 25(4):315-36. PubMed ID: 25440108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pros and cons of new oral anticoagulants.
    Bauer KA
    Hematology Am Soc Hematol Educ Program; 2013; 2013():464-70. PubMed ID: 24319220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease.
    Voukalis C; Lip GY; Shantsila E
    Expert Opin Pharmacother; 2016 Oct; 17(15):2033-47. PubMed ID: 27667112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis.
    Wang KL; Lip GY; Lin SJ; Chiang CE
    Stroke; 2015 Sep; 46(9):2555-61. PubMed ID: 26304863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke.
    Yaghi S; Kamel H; Elkind MS
    Neurology; 2015 Sep; 85(12):1078-84. PubMed ID: 26187229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Portuguese Observational Study of Ischaemic Stroke in Patients Medicated with Non-Vitamin K Antagonist Oral Anticoagulants.
    Beato-Coelho J; Marto JP; Alves JN; Marques-Matos C; Calado S; Araújo J; Cunha L; Pinho J; Azevedo E; Viana-Baptista M; Sargento-Freitas J
    Eur Neurol; 2018; 79(1-2):108-112. PubMed ID: 29421803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New oral anticoagulants versus vitamin K antagonists before cardioversion of atrial fibrillation: a meta-analysis of data from 4 randomized trials.
    Andò G; Trio O; Carerj S
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):577-83. PubMed ID: 25797595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
    Becattini C; Vedovati MC; Agnelli G
    Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-Vitamin K Antagonist Oral Anticoagulants: The Clinician's New Challenge.
    Yorkgitis BK; Zhang J; Rappold JF
    J Am Osteopath Assoc; 2015 Oct; 115(10):612-21. PubMed ID: 26414714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.
    Deitelzweig S
    Cardiovasc Ther; 2014 Apr; 32(2):74-81. PubMed ID: 24119252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events.
    Mekaj YH; Mekaj AY; Duci SB; Miftari EI
    Ther Clin Risk Manag; 2015; 11():967-77. PubMed ID: 26150723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel oral anticoagulants in non-valvular atrial fibrillation.
    Potpara TS; Lip GY
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):115-29. PubMed ID: 23953900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.
    Heidbuchel H; Verhamme P; Alings M; Antz M; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P
    Eur Heart J; 2013 Jul; 34(27):2094-106. PubMed ID: 23625209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants.
    Haft JI
    Clin Appl Thromb Hemost; 2013 Jun; 19(3):241-8. PubMed ID: 22952215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants.
    Caturano A; Galiero R; Pafundi PC
    Medicina (Kaunas); 2019 Sep; 55(10):. PubMed ID: 31547188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.